Related Experiment Video

Updated: Jul 10, 2026

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)
09:39

Targeted Antibody Blocking by a Dual-Functional Conjugate of Antigenic Peptide and Fc-III Mimetics (DCAF)

Published on: September 17, 2019

HDAC inhibitors: a potential new category of anti-tumor agents

Li Na Pan1, Jun Lu, Baiqu Huang

  • 1Key Laboratory of Molecular Epigenetics of MOE, Institute of Genetics and Cytology, Northeast Normal University, Changchun 130024, China.

Cellular & Molecular Immunology
|November 3, 2007
PubMed

Insights

Histone deacetylase (HDAC) inhibitors show promise in cancer therapy by reversing epigenetic silencing of tumor suppressor genes. Further research is needed to fully understand their mechanisms and clinical applications.

Area of Science:

  • Oncology
  • Epigenetics
  • Molecular Biology

Background:

  • Overexpression of histone deacetylases (HDACs) leads to epigenetic silencing of tumor suppressor genes, contributing to cancer development.
  • HDAC inhibitors offer a therapeutic strategy by blocking HDAC activity, restoring gene expression, and inducing cancer cell death.

Purpose of the Study:

  • To review recent advancements in the development of anti-cancer HDAC inhibitors.
  • To discuss the potential clinical value and therapeutic applications of HDAC inhibitors in cancer treatment.

Main Methods:

  • Literature review of recent studies on HDAC inhibitors in cancer therapy.
  • Analysis of the mechanisms of action and clinical potential of various HDAC inhibitors.

Main Results:

  • HDAC inhibitors can restore tumor suppressor gene expression and induce cancer cell differentiation, growth arrest, and apoptosis.
  • The precise mechanisms of HDAC inhibitor-induced cell death and the roles of individual inhibitors require further elucidation.

Conclusions:

  • HDAC inhibitors represent a promising class of anti-cancer agents with significant therapeutic potential.
  • Further investigation into their mechanisms, clinical utility, and synergistic effects with other therapies is warranted.

More Related Videos

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting11:58

Initial Evaluation of Antibody-conjugates Modified with Viral-derived Peptides for Increasing Cellular Accumulation and Improving Tumor Targeting

Published on: March 8, 2018

Assays for Validating Histone Acetyltransferase Inhibitors09:11

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Related Concept Videos

Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...